AVE 33.3% 0.2¢ avecho biotechnology limited

it`s the balance sheet stupid, page-19

  1. 5,756 Posts.
    lightbulb Created with Sketch. 308
    KC there is a reasonable chance that BodyShaper can raise enough cash this year with the international rollout to fund OxyPatch wholly.

    Definately by this time next year if POH are prepared to delay oxypatch a little to ensure full control. Whats another 6 months when we have been so patient?

    I'm sure a partner locked in is the kind of thing the market wants. But maybe we should just be a little cute here and see what BodyShaper sales are after 3 full months after full retail release?

    Weve speculated long and hard about what BodyShaper may be able to do so lets give it the first half of the game in the centre and really see what it can do.
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.